Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient
Age at least 18 years at the time of Tresiba® initiation
T1DM or insulin-treated T2DM patients
Switched to Tresiba® (with or without prandial insulin) after any basal insulin (with or without prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with Tresiba® at the time of patient selection
Previously treated with any basal insulin (with or without prandial insulin) for at least 6 months prior to switching to Tresiba®
At least one documented medical visit in the first 9 months after Tresiba® initiation
Minimum available data at the time of Tresiba® initiation: age, type of diabetes, HbA1c (Glycated haemoglobin), duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site of at least 1 year, and an eGFR (Estimated glomerular filtration rate )value in the last 12 months
You may not be if
Previous participation in this study. Participation is defined as having signed the Informed Consent
Participation in a diabetes clinical trial or receipt of any investigational medicinal product up to 12 months before or any time after the initiation of Tresiba®
Current participation in another non-interventional study on insulin degludec (Tresiba®)
Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba®
Clareo Health | Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
